VP WW Medical - Head of Portfolio Strategy Biomarkers & Early Assets Hematology & Oncology Biotechnology & Pharmaceuticals - Summit, NJ at Geebo

VP WW Medical - Head of Portfolio Strategy Biomarkers & Early Assets Hematology & Oncology

Working with UsChallenging.
Meaningful.
Life-changing.
Those aren t words that are usually associated with a job.
But working at Bristol Myers Squibb is anything but usual.
Here, uniquely interesting work happens every day, in every department.
From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it.
You ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams rich in diversity.
Take your career farther than you thought possible.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment.
We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Read more:
careers.
bms.
com/working-with-us.
Job Description:
Head of WWHM Portfolio Strategy & Hematology Oncology Early Assets Biomarkers.
ROLE TITLE:
VP WW Medical - Head of Portfolio Strategy Biomarkers & Early Assets Hematology & OncologyHIRING MANAGER:
Ridwaan JhetamLOCATION:
Boudry, Switzerland / Summit, NJROLE SUMMARYHead of WWHM Portfolio Strategy, Biomarkers & Hematology & Oncology Early Assets.
will lead a team to provide strategic medical input across the Portfolio to maximize health outcomes, clinical adoption and patient access across for BMS Assets across Hematology, Cell Therapies and early assets across Hematology & Oncology Therapy areas.
This is a senior medical leadership role reporting to the WW Medical Head of Hematology and will be a member of the WW Hematology & WW Oncology Medical Leadership Teams.
RESPONSIBILITIES Collaboration with Discovery, Early Development, Translational Research, Early Transition Assets to support optimal execution of personalized care and biomarker/diagnostic strategy for priority programs and ensure proper understanding and communication thereof both internally and externally.
Lead the creation of an early integrated evidence plan that will differentiate the endpoints and outcomes for clinical trials and real-world evidence generation that are meaningful for physicians to change clinical practice, maximize patient access and outcomes.
Shape Portfolio strategy, IEPs and CCF plans beyond regulatory requirements for local unmet needs and standard of care.
Drive cross functional shaping for programs across the hematology & Oncology portfolio as they advance from discovery research through REDOC/ governance milestones.
Lead understanding of clinical practice, unmet need, guidelines, and patient journey in the different therapeutic areas, establishing strong early Medical Affairs plans.
Provide Priority new program strategic assessments, so the most transformational assets are prioritized.
Key input to define the optimal target product profile (TPP) for any new or early-stage assets for transformational impact for patients.
Function as a key member in discussions of BD/in-licensing and out-licensing of assets, collaborating closely with the business development team.
Support of R&D, through the drug development process; and evaluation of business development and pipeline opportunities.
Ensure deep local and stakeholder insights to inform shaping of pipeline assets.
Lead and coach members of the Early Asset Medical Team.
As a member of the WW Heme &oncology Medical Affairs Leadership team, contribute to leadership of the overall and broader medical roadmapEstablish robust portfolio cross-asset medical strategy to maximize life cycle management with emphasis on maximizing launch and patient access to Hematology and Cell Therapies, partnering with disease area heads and key Market HeadsPartner with MEG and GDD, GDO, HEOR and Disease Area Heads, to portfolio level evidence generation strategy for Hematology and Cell Therapies leading to optimal prioritization and earliest maximization and Life Cycle Management of our assets.
Partner across the portfolio with Markets and Disease Area leads, and MEG to align on priorities related to evidence generation strategy to appropriately inform and support prioritization of local evidence generation studies and asset related strategies and projects.
Appropriately collaborate with and engage Market Access/Health Economics Outcomes Research (HEOR) to inform regional data gaps and mitigation strategies.
Integrate Global Development Operations (GDO) and Regional Clinical Operations (RCO) in strategy definition and feasibility for successful execution of priority Oncology & Hematology/ Cell Therapy products.
Partner with Disease Area leads, Strategic collaborations and GDD and GDO to identify and facilitate the establishment of research collaborations with academic, governmental and research and treatment centres in line with WW Medical, Major Markets and/or Intercon, and country priorities, including pre-clinical, translational, clinical, RWE and digital health programs.
Drive early medical expert and scientific engagement in key strategic countries.
Ensure strong Scientific Communications plans are being executed in the different therapeutic areasPartner with Disease Area leads and IT partners; analytics team to identify and facilitate the establishment of innovative omnichannel and AI and ML based solutions; partnering with technology collaborations in line with business prioritiesFoster and facilitate, in conjunction with Disease Area Heads, appropriate external TL engagement and support development of patient access and reimbursement strategies with regards to HTA related matters, including during Congresses.
Collaborate with Commercial Portfolio Strategy leads to deliver Hematology and Oncology Franchise Strategy and ensure implementation and execution of aligned Medical Portfolio Strategy with all WW Medical Leads and other critical Medical Stakeholders (including Medical Markets, HEOR and Medical Capabilities).
Alignment and oversight of medical strategic priorities to ensure execution of global medical plans and provide strategic direction to the stakeholders of the Medical Matrix Teams, including the Medical Markets, to ensure global alignment for the medical plans.
REQUIRED QUALIFICATIONS AND EXPERIENCEPharm D /PhD /MD- preferably Board-certified hematologist/oncologist10
years of development/clinical and medical experience with an emphasis on Global or market-based Medical Affairs experienceExpertise in leading through influence and building collaborative networksHas strong business acumen to align the WW Hematology and Oncology Medical TAs to the business strategies and prioritiesEnterprise mindset with demonstrated success delivering results in a matrix environment and in a variety of business situationsKnowledge of Research, Discovery and Drug Development, reimbursement including leveraging of RWE, and ability to communicate data in an impactful wayTrack record of building strong internal and external networksAbility to manage complexity and cultural diversityPrevious in country as well as global experience in medical affairsCreation and management of successful cross-functional and multi-disciplinary teams in changing competitive environment, changing product technology, and changing customer needsExcellent communication and organization skillsTrack record of innovation and willingness to charter new watersDemonstrated customer focus orientation and credibility with customersPossess strong business acumen and financial skills; has P&L experience or budget experienceIf you come across a role that intrigues you but doesn t perfectly line up with your resume, we encourage you to apply anyway.
You could be one step away from work that will transform your life and career.
Uniquely Interesting Work, Life-changing CareersWith a single vision as inspiring as Transforming patients lives through science , every BMS employee plays an integral role in work that goes far beyond ordinary.
Each of us is empowered to apply our individual talents and unique perspectives in an inclusive culture, promoting diversity in clinical trials, while our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
On-site ProtocolPhysical presence at the BMS worksite or physical presence in the field is a necessary job function of this role, which the Company deems critical to collaboration, innovation, productivity, employee well-being and engagement, and it enhances the Company culture.
BMS is dedicated to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace accommodations/adjustments and ongoing support in their roles.
Applicants can request a reasonable workplace accommodation/adjustment prior to accepting a job offer.
If you require reasonable accommodations/adjustments in completing this application, or in any part of the recruitment process, direct your inquiries to adastaffingsupport@bms.
com.
Visit careers.
bms.
com/eeo-accessibility to access our complete Equal Employment Opportunity statement.
BMS cares about your well-being and the well-being of our staff, customers, patients, and communities.
As a result, the Company strongly recommends that all employees be fully vaccinated for Covid-19 and keep up to date with Covid-19 boosters.
BMS will consider for employment qualified applicants with arrest and conviction records, pursuant to applicable laws in your area.
Any data processed in connection with role applications will be treated in accordance with applicable data privacy policies and regulations.
.
Estimated Salary: $20 to $28 per hour based on qualifications.

Don't Be a Victim of Fraud

  • Electronic Scams
  • Home-based jobs
  • Fake Rentals
  • Bad Buyers
  • Non-Existent Merchandise
  • Secondhand Items
  • More...

Don't Be Fooled

The fraudster will send a check to the victim who has accepted a job. The check can be for multiple reasons such as signing bonus, supplies, etc. The victim will be instructed to deposit the check and use the money for any of these reasons and then instructed to send the remaining funds to the fraudster. The check will bounce and the victim is left responsible.